Response to the comment by Rémy Boussageon (The placebo effect: Still under a cloud of confusion) on the article by Berthelot et al. (The placebo effect in rheumatology)

Joint Bone Spine

Volumn 78, Issue 4, 2011, Pages 433-434

  Berthelot, Jean Marie ^a  

^a HÔTEL DIEU   (France)

Author keywords

Hawthorne effect; Placebo effect; Regression to the mean

Indexed keywords

GLUCOSAMINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUPUNCTURE; ANALGESIA; HAWTHORNE EFFECT; HEALTH CARE PERSONNEL; HUMAN; LETTER; META ANALYSIS (TOPIC); PERCUTANEOUS VERTEBROPLASTY; PLACEBO EFFECT; RHEUMATOLOGY; VISUAL ANALOG SCALE;

EID: 79960637992     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.03.016     Document Type: Letter

References (5)

1. Berthelot J.M. The placebo effect in rheumatology: new data. Joint Bone Spine 2011, 78:161-165.
2. Zhang W., Robertson J., Jones A.C., et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008, 67:1716-1723.
3. Colloca L., Lopiano L., Lanotte M., et al. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004, 3:679-684.
4. Hrobjartsoon A., Gotzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001, 344:1594-1602.
5. Wolfe F., Michaud K. The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. Arthritis Rheum 2010, 62:S-475 127. [abstract 1132].